Core A will provide cytogenetics and molecular genetics support to the various projects of this application. Karyotype analysis will be provided on all patients' samples as a function of the status of the patient's disease and therapy. In addition, all cell lines maintained in culture or established from patient samples will be analyzed for chromosomal abnormalities or alterations. The need exists for a better understanding of the chromosomal events which occur during initiation and progression of MM so that particular molecular lesions can be targeted for further study. Coupled with the more standard chromosomal analysis, this core will also provide chromosome analysis by fluorescence in situ hybridization (FISH). This approach allows increased sensitivity, speed, less labor and ease of data interpretation when compared to more traditional analysis. FISH will initially be applied to interesting patient samples identified by karyotype analysis and then expanded to additional samples in the latter years of the project. Specifically, FISH will be used to examine for chromosomal abnormalities, such as translocations or deletions, to identify small marker chromosomes, to determine ploidy or aneuploidy to interphase nuclei, and to rapidly localized DNA sequences to individual chromosomes. this core will also provide information about the involvement of oncogenes and tumor suppressor genes in the disease process. In particular, the core will measure mutations in ras, the level of myc expression, alterations in p53 and Rb gene structure, and loss of heterozygosity of chromosome 13 and 17 in MM patients. In addition, we will use PCR for the detection of monoclonal B-cell populations. the detection of residual disease will become important as complete remissions by immunofixation criteria are more frequently achieved with BMT programs. Karyotype analysis will be performed by high resolution G-banding analysis. FISH will utilize biotin-labeled DNA probes for individual chromosomes which will be detected using a double antibody approach. Molecular analysis will be performed by PCR, Northern Blot Analysis, and direct sequences analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA055819-04S2
Application #
6102741
Study Section
Project Start
1996-02-01
Project End
1999-01-31
Budget Start
Budget End
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Rasche, L; Alapat, D; Kumar, M et al. (2018) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia :
Went, Molly; Sud, Amit; Försti, Asta et al. (2018) Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun 9:3707
Mehdi, Syed J; Johnson, Sarah K; Epstein, Joshua et al. (2018) Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol :
Rasche, Leo; Angtuaco, Edgardo J; Alpe, Terri L et al. (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132:59-66
Went, M; Sud, A; Law, P J et al. (2017) Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7:e573
McDonald, James E; Kessler, Marcus M; Gardner, Michael W et al. (2017) Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res 23:1981-1987
Rasche, Leo; Weinhold, Niels; Morgan, Gareth J et al. (2017) Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 55:190-199
Rasche, L; Chavan, S S; Stephens, O W et al. (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:268
Jethava, Yogesh S; Mitchell, Alan; Epstein, Joshua et al. (2017) Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res 23:2665-2672
Schinke, Carolina; Hoering, Antje; Wang, Hongwei et al. (2017) The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica 102:e313-e316

Showing the most recent 10 out of 290 publications